Sacubitril is a neprilysin inhibitor, one part of ENTRESTO, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction ENTRESTO will be a blockbuster drug in near future.
*The following content is generated by AI and is for reference only.
Sacubitril Intermediate (CAS No. 1012341-50-2) is a critical pharmaceutical building block utilized in the synthesis of sacubitril, the active moiety of the innovative cardiovascular drug Entresto® (sacubitril/valsartan). Chemically identified by its specific molecular formula C20H26N2O5, this intermediate serves as an essential precursor for manufacturing the Angiotensin Receptor Neprilysin Inhibitor (ARNI) class of medications. The compound features a complex structure containing a pyrazole ring and specific ester functionalities that are pivotal for its biological activity once converted into the final therapeutic agent.
In the global pharmaceutical supply chain, Sacubitril Intermediate plays a non-negotiable role in ensuring the consistent production of life-saving treatments for heart failure. Heart failure affects millions worldwide, often leading to reduced ejection fraction and significant morbidity. By inhibiting neprilysin while simultaneously blocking angiotensin II receptors, the final drug derived from this intermediate effectively lowers blood pressure, reduces cardiac afterload, and prevents harmful remodeling of the heart muscle. Consequently, high-purity batches of this intermediate are strictly required by API manufacturers to meet rigorous regulatory standards set by agencies such as the FDA and EMA.
The synthesis process involving CAS 1012341-50-2 demands precise control over reaction conditions to maintain stereochemical integrity and minimize impurities. Pharmaceutical companies sourcing this material prioritize suppliers who can provide comprehensive Certificate of Analysis (CoA) documentation, confirming identity, purity levels typically exceeding 98%, and adherence to Good Manufacturing Practices (GMP). Beyond clinical applications, research institutions also utilize this intermediate for pharmacological studies aimed at understanding neurohormonal pathways in cardiovascular diseases. As the demand for effective heart failure therapies continues to rise globally, the strategic importance of maintaining a robust supply of Sacubitril Intermediate remains paramount for advancing patient care and medical innovation in cardiology.